TY - JOUR
T1 - ANMCO Position Paper
T2 - long-term follow-up of patients with pulmonary thromboembolism
AU - D'Agostino, Carlo
AU - Zonzin, Pietro
AU - Enea, Iolanda
AU - Gulizia, Michele Massimo
AU - Ageno, Walter
AU - Agostoni, Piergiuseppe
AU - Azzarito, Michele
AU - Becattini, Cecilia
AU - Bongarzoni, Amedeo
AU - Bux, Francesca
AU - Casazza, Franco
AU - Corrieri, Nicoletta
AU - D'Alto, Michele
AU - D'Amato, Nicola
AU - D'Armini, Andrea Maria
AU - De Natale, Maria Grazia
AU - Di Minno, Giovanni
AU - Favretto, Giuseppe
AU - Filippi, Lucia
AU - Grazioli, Valentina
AU - Palareti, Gualtiero
AU - Pesavento, Raffaele
AU - Roncon, Loris
AU - Scelsi, Laura
AU - Tufano, Antonella
PY - 2017/5
Y1 - 2017/5
N2 - Venous thromboembolism (VTE), including pulmonary embolism and deep venous thrombosis, is the third most common cause of cardiovascular death. The management of the acute phase of VTE has already been described in several guidelines. However, the management of the follow-up (FU) of these patients has been poorly defined. This consensus document, created by the Italian cardiologists, wants to clarify this issue using the currently available evidence in VTE. Clinical and instrumental data acquired during the acute phase of the disease are the cornerstone for planning the FU. Acquired or congenital thrombophilic disorders could be identified in apparently unprovoked VTE during the FU. In other cases, an occult cancer could be discovered after a VTE. The main targets of the post-acute management are to prevent recurrence of VTE and to identify the patients who can develop a chronic thromboembolic pulmonary hypertension. Knowledge of pathophysiology and therapeutic approaches is fundamental to decide the most appropriate long-term treatment. Moreover, prognostic stratification during the FU should be constantly updated on the basis of the new evidence acquired. Currently, the cornerstone of VTE treatment is represented by both the oral and the parenteral anticoagulation. Novel oral anticoagulants should be an interesting alternative in the long-term treatment.
AB - Venous thromboembolism (VTE), including pulmonary embolism and deep venous thrombosis, is the third most common cause of cardiovascular death. The management of the acute phase of VTE has already been described in several guidelines. However, the management of the follow-up (FU) of these patients has been poorly defined. This consensus document, created by the Italian cardiologists, wants to clarify this issue using the currently available evidence in VTE. Clinical and instrumental data acquired during the acute phase of the disease are the cornerstone for planning the FU. Acquired or congenital thrombophilic disorders could be identified in apparently unprovoked VTE during the FU. In other cases, an occult cancer could be discovered after a VTE. The main targets of the post-acute management are to prevent recurrence of VTE and to identify the patients who can develop a chronic thromboembolic pulmonary hypertension. Knowledge of pathophysiology and therapeutic approaches is fundamental to decide the most appropriate long-term treatment. Moreover, prognostic stratification during the FU should be constantly updated on the basis of the new evidence acquired. Currently, the cornerstone of VTE treatment is represented by both the oral and the parenteral anticoagulation. Novel oral anticoagulants should be an interesting alternative in the long-term treatment.
KW - Journal Article
U2 - 10.1093/eurheartj/sux030
DO - 10.1093/eurheartj/sux030
M3 - Article
C2 - 28751848
VL - 19
SP - D309-D332
JO - European Heart Journal, Supplement
JF - European Heart Journal, Supplement
SN - 1520-765X
IS - Suppl D
ER -